CN103044450B - 头孢唑肟钠化合物、其制备方法及其药物组合物 - Google Patents
头孢唑肟钠化合物、其制备方法及其药物组合物 Download PDFInfo
- Publication number
- CN103044450B CN103044450B CN2013100030252A CN201310003025A CN103044450B CN 103044450 B CN103044450 B CN 103044450B CN 2013100030252 A CN2013100030252 A CN 2013100030252A CN 201310003025 A CN201310003025 A CN 201310003025A CN 103044450 B CN103044450 B CN 103044450B
- Authority
- CN
- China
- Prior art keywords
- ceftizoxime sodium
- ceftizoxime
- sodium
- preparation
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ADLFUPFRVXCDMO-LIGXYSTNSA-M ceftizoxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=CCS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 ADLFUPFRVXCDMO-LIGXYSTNSA-M 0.000 title claims abstract description 96
- 229960000636 ceftizoxime sodium Drugs 0.000 title claims abstract description 95
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 title abstract description 12
- 229940079593 drug Drugs 0.000 title abstract description 6
- 239000000203 mixture Substances 0.000 title abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Substances [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 22
- 235000011121 sodium hydroxide Nutrition 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 239000012046 mixed solvent Substances 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 5
- 238000005261 decarburization Methods 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000012047 saturated solution Substances 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000007951 isotonicity adjuster Substances 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 2
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 11
- 238000003860 storage Methods 0.000 abstract description 8
- 239000000047 product Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910017488 Cu K Inorganic materials 0.000 description 3
- 229910017541 Cu-K Inorganic materials 0.000 description 3
- 230000005260 alpha ray Effects 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229950003476 aminothiazole Drugs 0.000 description 2
- 230000002358 autolytic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960001991 ceftizoxime Drugs 0.000 description 2
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- UDTVQXNZIKQKOI-BAFYGKSASA-N (6r)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-4-carboxylic acid Chemical compound C1=CC(C(=O)O)S[C@@H]2CC(=O)N21 UDTVQXNZIKQKOI-BAFYGKSASA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010058674 Pelvic Infection Diseases 0.000 description 1
- 101710202686 Penicillin-sensitive transpeptidase Proteins 0.000 description 1
- 101710146026 Peptidoglycan D,D-transpeptidase FtsI Proteins 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 101710181936 Phosphate-binding protein PstS 3 Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001782 cephems Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- -1 methoxyimino Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- DSIJXEVOJMBKAM-UHFFFAOYSA-M sodium;2-methyloct-2-enoate Chemical compound [Na+].CCCCCC=C(C)C([O-])=O DSIJXEVOJMBKAM-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
0个月 | 1个月 | 3个月 | 6个月 | 9个月 | |
1 | 99.85% | 99.84% | 99.83% | 99.81% | 99.63% |
2 | 99.71% | 99.70% | 99.68% | 99.65% | 99.45% |
3 | 99.79% | 99.78% | 99.76% | 99.70% | 99.52% |
4 | 99.65% | 99.62% | 99.55% | 99.40% | 99.14% |
5 | 99.74% | 99.72% | 99.61% | 99.35% | 99.08% |
6 | 99.85% | 99.78% | 99.45% | 99.15% | 98.52% |
0个月 | 3个月 | 6个月 | 9个月 | 15个月 | 24个月 | |
1 | 99.85% | 99.83% | 99.80% | 99.75% | 99.60% | 99.81% |
2 | 99.71% | 99.69% | 99.65% | 99.60% | 99.41% | 99.65% |
3 | 99.79% | 99.76% | 99.72% | 99.67% | 99.50% | 99.71% |
4 | 99.65% | 99.60% | 99.50% | 99.38% | 99.11% | 99.58% |
5 | 99.74% | 99.70% | 99.65% | 99.30% | 99.04% | 99.70% |
6 | 99.85% | 99.75% | 99.40% | 99.11% | 98.50% | 99.74% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013100030252A CN103044450B (zh) | 2013-01-05 | 2013-01-05 | 头孢唑肟钠化合物、其制备方法及其药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013100030252A CN103044450B (zh) | 2013-01-05 | 2013-01-05 | 头孢唑肟钠化合物、其制备方法及其药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103044450A CN103044450A (zh) | 2013-04-17 |
CN103044450B true CN103044450B (zh) | 2013-11-20 |
Family
ID=48057332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013100030252A Active CN103044450B (zh) | 2013-01-05 | 2013-01-05 | 头孢唑肟钠化合物、其制备方法及其药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103044450B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103910750B (zh) * | 2014-04-18 | 2016-05-11 | 悦康药业集团有限公司 | 一种头孢唑肟钠化合物 |
CN105037390A (zh) * | 2015-05-28 | 2015-11-11 | 浙江长典医药有限公司 | 一种小儿用头孢唑肟钠化合物实体及其制剂 |
CN105622635B (zh) * | 2016-03-10 | 2017-03-15 | 重庆福安药业集团庆余堂制药有限公司 | 一种减少过敏反应的头孢唑肟钠新晶型及其制剂 |
CN109160920A (zh) * | 2017-07-20 | 2019-01-08 | 海南美大制药有限公司 | 一种一水头孢唑肟钠化合物 |
CN109160921A (zh) * | 2017-07-26 | 2019-01-08 | 王秀香 | 一种1/2水头孢唑肟钠化合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5726692A (en) * | 1980-07-22 | 1982-02-12 | Fujisawa Pharmaceut Co Ltd | Preparation of stable crystal of salt of ceftizoxime |
CN101781316A (zh) * | 2010-03-17 | 2010-07-21 | 刘力 | 头孢唑肟钠结晶水合物及其制备方法和用途 |
CN101843589B (zh) * | 2010-06-13 | 2011-05-18 | 山东罗欣药业股份有限公司 | 注射用头孢唑肟钠组合物无菌粉末 |
-
2013
- 2013-01-05 CN CN2013100030252A patent/CN103044450B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103044450A (zh) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103044450B (zh) | 头孢唑肟钠化合物、其制备方法及其药物组合物 | |
ES2547258T3 (es) | Sistemas de administración transdérmica de antibióticos beta-lactama | |
TWI248363B (en) | Methods of treatment and formulations of cephalosporin | |
ES2691680T3 (es) | Daptomicina en forma cristalina y su preparación | |
CN110279698B (zh) | 头孢特咯瓒抗生素组合物 | |
JPH0128036B2 (zh) | ||
CN108135887A (zh) | 噁唑烷酮化合物及其作为抗菌剂的使用方法 | |
CN102180890B (zh) | 头孢硫脒结晶物及其用途 | |
CN102936254B (zh) | 一种含有头孢唑肟钠化合物的药物组合物 | |
CN104910186A (zh) | 一种头孢硫脒化合物 | |
WO2018177218A1 (zh) | 3,5-二取代甲基吡唑并[1,5-a]嘧啶-7-酚盐类似物和衍生物制备方法和用途 | |
CN101074235B (zh) | 头孢硫脒醇水化合物及其制备方法 | |
CN103467494B (zh) | 一种头孢地尼的新晶型及其制备方法 | |
CA2949328A1 (en) | Low substituted polymyxins and compositions thereof | |
CN101565105A (zh) | 注射用头孢唑肟钠粉针制剂的制备方法及其用途 | |
AU2012327237A1 (en) | Compositions of tigecycline and uses thereof | |
CN102247375B (zh) | 一种注射用头孢替坦二钠及其制备方法 | |
CN105147599B (zh) | 硫酸奈替米星注射液和制法 | |
AU2012389714B2 (en) | Cocrystal of piperacillin sodium and sulbactam sodium and preparation method thereof, as well as pharmaceutical compositions containing same and uses thereof | |
CN104530082A (zh) | 头孢硫脒化合物 | |
CN105622635B (zh) | 一种减少过敏反应的头孢唑肟钠新晶型及其制剂 | |
CN101747347A (zh) | 低结晶水头孢曲松钠晶体及其制备方法 | |
CN103113390A (zh) | 一种舒巴坦钠化合物及其与美洛西林钠的药物组合物 | |
WO2021228008A1 (zh) | 头孢呋辛镁化合物、组合物、制备方法及用途 | |
CN105213301B (zh) | 硫酸奈替米星注射液及其质控方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130417 Assignee: Zhuhai Kinhoo Pharmaceutical Co., Ltd. Assignor: Huang Jinxiu Contract record no.: 2013990000838 Denomination of invention: Ceftizoxime sodium compound and preparation method and drug composition of ceftizoxime sodium compound Granted publication date: 20131120 License type: Exclusive License Record date: 20131213 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: ZHUHAI KINHOO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HUANG JINXIU Effective date: 20140506 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140506 Address after: Zhuhai City Jinwan District biological Industrial Zone Gold Coast Patentee after: Zhuhai Kinhoo Pharmaceutical Co., Ltd. Address before: 6, 1108, building 208, 519001 lemon Creek Road, Xiangzhou District, Guangdong, Zhuhai, Xiangzhou Patentee before: Huang Jinxiu |
|
CP03 | Change of name, title or address |
Address after: 519041 Guangdong Province, Zhuhai City Industrial Zone, Jinwan District biological Patentee after: Jin Hong pharmaceutical Limited by Share Ltd Address before: Zhuhai City Jinwan District biological Industrial Zone Gold Coast Patentee before: Zhuhai Kinhoo Pharmaceutical Co., Ltd. |
|
CP03 | Change of name, title or address |